Coherus Oncology Inc (CHRS) Stock Price, Quote, News & History

CHRSNASDAQ
$1.41
-0.05-3.42%
At close: Aug 28, 5:00 PM EST
$1.39
-0.02-1.42%
After Hours: Aug 28, 6:57 PM EST

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-186.03M
Investing Cash Flow (TTM)
-9.78M
Financing Cash Flow (TTM)
61.82M
Free Cash Flow (TTM)
-186.03M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
-133.99M

Analyst Trends and Forecast

1
May
1
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$152.19M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
3.80
PB Ratio (TTM)
3.72
Earnings Yield % (TTM)
-84.64%
Earnings Yield % (FWD)
-56.66%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$0.39

Company Debt

Total Debt
$37.25M
LT Debt
$37.25M
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$47.77M
Total Cash
$82.92M
Debt to Equity
0.65
Issuance of Debt (TTM)
-$47.77M
Repayment of Debt (TTM)
-$47.77M

Key Statistics

Open
$1.45
Close
$1.41
Volume / Avg.
605.09K / 1.01M
Day Range
$1.40 - $1.48
52 Wk Range
1.09 - 2.62
Market Cap
$214.76M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
52
Short Interest
16%
Days to Cover
19.71

About

Sector
Health Care
Industry
Biotechnology
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and o...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Coherus Oncology (CHRS) stock?

A

You can purchase shares of Coherus Oncology (NASDAQ:CHRS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Coherus Oncology (CHRS) competitors?

Q

What is the forecast, or price target, for Coherus Oncology (CHRS) stock?

A

Coherus Oncology has a consensus price target of $7.12.

Q

What is the current price for Coherus Oncology (CHRS)?

A

The stock price for Coherus Oncology (NASDAQ: CHRS) is $1.39 last updated August 28, 2026 at 6:57 PM EDT.

Q

Does Coherus Oncology (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus Oncology.

Q

When is Coherus Oncology (NASDAQ:CHRS) reporting earnings?

A

Coherus Oncology does not have any upcoming earnings scheduled.

Q

Is Coherus Oncology (CHRS) going to split?

A

There is no upcoming split for Coherus Oncology.

Q

What sector and industry does Coherus Oncology (CHRS) operate in?

A

Coherus Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.